Rhizomelic Chondrodysplasia Punctata (RCDP)
A severe inherited peroxisomal disorder affecting plasmalogen synthesis, causing characteristic skeletal shortening, cataracts, and significant developmental impact from early infancy.
- Genetic testing confirmatory
- Multidisciplinary supportive care
- Specialist coordination available
- Inheritance Pattern
- Autosomal Recessive
- Genes Involved
- PEX7, GNPAT, AGPS, FAR1
- Onset
- Present at Birth
- Care Focus
- Multidisciplinary Supportive Care
Condition Overview
Rhizomelic Chondrodysplasia Punctata (RCDP) is a rare, severe inherited disorder of peroxisomal function that disrupts the synthesis of plasmalogens, a class of lipids essential for normal brain and skeletal development. It is caused by mutations in PEX7, GNPAT, AGPS, or, rarely, FAR1.
RCDP is characterized from birth by disproportionate shortening of the upper arms and thighs (rhizomelia), distinctive facial features, cataracts, and significant developmental delay. Severity can vary somewhat between the recognized subtypes, but most affected infants have substantial medical needs from early infancy.
Because RCDP affects multiple organ systems simultaneously, care is most effective when coordinated across genetics, orthopedics, ophthalmology, and developmental specialists from the time of diagnosis.
Types and Subtypes
RCDP is classified into subtypes based on the specific gene involved, though clinical features overlap substantially.
Symptoms and Signs
RCDP typically presents at birth with characteristic skeletal and facial features, alongside significant developmental impact.
Causes and Risk Factors
RCDP is caused entirely by inherited mutations disrupting peroxisomal plasmalogen synthesis; it is not caused by anything during pregnancy or after birth.
Diagnosis and Investigations
Diagnosis combines clinical findings at birth with biochemical and genetic confirmation.
Disease Severity Stratification
RCDP is not staged like cancer; severity classification is based on biochemical findings and the degree of organ system involvement.
Standard Treatment Options
There is no cure for RCDP; care focuses on supportive management across multiple organ systems.
Advanced & Emerging Therapies
There is currently no disease-modifying therapy for RCDP; research is focused on understanding plasmalogen replacement and gene-targeted approaches.
Investigational
Plasmalogen replacement approaches
Early research is exploring whether supplementing plasmalogens or their precursors could improve outcomes.
Precision Medicine
Genotype-informed supportive care planning
Care plans are increasingly tailored based on the confirmed genetic subtype and biochemical severity.
Gene Therapy
Gene-targeted research approaches
Preclinical research into gene-based correction strategies for peroxisomal disorders is ongoing but not yet clinically available for RCDP.
Biomarkers & Precision Medicine
Biochemical and genetic markers are central to confirming diagnosis and subtype classification.
When a Second Opinion May Be Important
Given the rarity and complexity of RCDP, specialist input can help families navigate care decisions with greater confidence.
Clinical Trials & Research
Prognosis & Outcome Factors
Prognosis in RCDP varies by subtype and severity of plasmalogen deficiency, and is generally guided by a child's individual clinical course rather than genotype alone.
Supportive Care and Living With RCDP
Ongoing multidisciplinary support helps families manage the wide-ranging effects of RCDP across infancy and childhood.
How CancerFax Helps You Explore Treatment Options
CancerFax can help review genetic and imaging reports, coordinate a specialist second opinion, and connect families with multidisciplinary centers experienced in managing RCDP.
Get a free case reviewFrequently Asked Questions
RCDP is a rare inherited peroxisomal disorder that disrupts plasmalogen synthesis, causing characteristic skeletal shortening, cataracts, and developmental delay from birth.
RCDP is usually apparent at birth, with shortened upper arms and thighs, distinctive facial features, and congenital cataracts.
RCDP is caused by inherited mutations in PEX7, GNPAT, AGPS, or FAR1, which disrupt the synthesis of plasmalogens needed for normal development.
Diagnosis combines clinical findings, reduced red blood cell plasmalogen levels, and confirmatory genetic testing.
There is currently no cure. Care focuses on supportive management of skeletal, visual, respiratory, and developmental needs.
Yes, RCDP is classified into types based on the gene involved—PEX7, GNPAT, AGPS, or FAR1—though clinical features overlap.
Yes, RCDP is inherited in an autosomal recessive pattern, meaning both parents must carry a mutated gene copy.
Yes, cataract surgery can be performed to support visual development when appropriate for the child.
Care typically involves genetics, orthopedics, ophthalmology, developmental pediatrics, and rehabilitation specialists.
Yes. CancerFax can help review medical and genetic reports, coordinate a second opinion, and connect families with multidisciplinary specialist centers experienced in managing RCDP.
Have an RCDP Diagnosis or Genetic Results to Review?
Share your reports with CancerFax to explore specialist second opinions and coordinated supportive care.